Your browser doesn't support javascript.
loading
Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.
van der Ree, Meike H; de Vree, J Marleen; Stelma, Femke; Willemse, Sophie; van der Valk, Marc; Rietdijk, Svend; Molenkamp, Richard; Schinkel, Janke; van Nuenen, Ad C; Beuers, Ulrich; Hadi, Salah; Harbers, Marten; van der Veer, Eva; Liu, Kai; Grundy, John; Patick, Amy K; Pavlicek, Adam; Blem, Jacqueline; Huang, Michael; Grint, Paul; Neben, Steven; Gibson, Neil W; Kootstra, Neeltje A; Reesink, Hendrik W.
Afiliação
  • van der Ree MH; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands.
  • de Vree JM; Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, Netherlands.
  • Stelma F; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands.
  • Willemse S; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands.
  • van der Valk M; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Internal Medicine, Division of Infectious Diseases, Center for Infection and Immunity Amsterdam, Academic Medical Center, Amsterdam, Netherlands.
  • Rietdijk S; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Onze Lieve Vrouwe Gasthuis, Oosterpark, Amsterdam, Netherlands.
  • Molenkamp R; Department of Medical Microbiology, Clinical Virology Laboratory, Academic Medical Center, Amsterdam, Netherlands.
  • Schinkel J; Department of Medical Microbiology, Clinical Virology Laboratory, Academic Medical Center, Amsterdam, Netherlands.
  • van Nuenen AC; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands.
  • Beuers U; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands.
  • Hadi S; PRA Health Sciences, Zuidlaren, the Netherlands.
  • Harbers M; PRA Health Sciences, Zuidlaren, the Netherlands.
  • van der Veer E; DDL Diagnostic Laboratory, Rijswijk, Netherlands.
  • Liu K; Regulus Therapeutics, San Diego, CA, USA.
  • Grundy J; Regulus Therapeutics, San Diego, CA, USA.
  • Patick AK; Regulus Therapeutics, San Diego, CA, USA.
  • Pavlicek A; Regulus Therapeutics, San Diego, CA, USA.
  • Blem J; Regulus Therapeutics, San Diego, CA, USA.
  • Huang M; Regulus Therapeutics, San Diego, CA, USA.
  • Grint P; Regulus Therapeutics, San Diego, CA, USA.
  • Neben S; Regulus Therapeutics, San Diego, CA, USA.
  • Gibson NW; Regulus Therapeutics, San Diego, CA, USA.
  • Kootstra NA; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands.
  • Reesink HW; Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands; Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands. Electronic address: h.w.reesink@amc.uva.nl.
Lancet ; 389(10070): 709-717, 2017 02 18.
Article em En | MEDLINE | ID: mdl-28087069

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C Crônica / MicroRNAs Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hepatite C Crônica / MicroRNAs Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article